- Home
- APPS vs FULC Comparison
APPS vs FULC Comparison
Compare APPS & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APPS
- FULC
- Stock Information
- Founded
- APPS N/A
- FULC 2015
- Country
- APPS United States
- FULC United States
- Employees
- APPS N/A
- FULC N/A
- Industry
- APPS Multi-Sector Companies
- FULC Biotechnology: Pharmaceutical Preparations
- Sector
- APPS Miscellaneous
- FULC Health Care
- Exchange
- APPS Nasdaq
- FULC Nasdaq
- Market Cap
- APPS 562.7M
- FULC 469.0M
- IPO Year
- APPS N/A
- FULC 2019
- Fundamental
- Price
- APPS $6.26
- FULC $9.36
- Analyst Decision
- APPS Buy
- FULC Buy
- Analyst Count
- APPS 3
- FULC 7
- Target Price
- APPS $4.83
- FULC $9.14
- AVG Volume (30 Days)
- APPS 2.7M
- FULC 536.5K
- Earning Date
- APPS 11-04-2025
- FULC 10-29-2025
- Dividend Yield
- APPS N/A
- FULC N/A
- EPS Growth
- APPS N/A
- FULC N/A
- EPS
- APPS N/A
- FULC N/A
- Revenue
- APPS $503,443,000.00
- FULC N/A
- Revenue This Year
- APPS $10.64
- FULC N/A
- Revenue Next Year
- APPS $11.24
- FULC N/A
- P/E Ratio
- APPS N/A
- FULC N/A
- Revenue Growth
- APPS N/A
- FULC 2752.05
- 52 Week Low
- APPS $1.18
- FULC $2.32
- 52 Week High
- APPS $7.77
- FULC $10.11
- Technical
- Relative Strength Index (RSI)
- APPS 50.18
- FULC 54.41
- Support Level
- APPS $6.07
- FULC $8.89
- Resistance Level
- APPS $6.92
- FULC $10.09
- Average True Range (ATR)
- APPS 0.45
- FULC 0.70
- MACD
- APPS -0.10
- FULC -0.04
- Stochastic Oscillator
- APPS 14.11
- FULC 59.44
About APPS Digital Turbine Inc.
Digital Turbine Inc is an independent mobile growth platform. It offers end-to-end products and solutions to all participants in the mobile application ecosystem, enabling brand discovery and advertising, user acquisition and engagement, and operational efficiency for advertisers. Its operating segments are On Device Solutions and App Growth Platform.
About FULC Fulcrum Therapeutics Inc.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.